207 related articles for article (PubMed ID: 20463065)
41. Structural basis for HIV-1 antagonism of host APOBEC3G via Cullin E3 ligase.
Ito F; Alvarez-Cabrera AL; Liu S; Yang H; Shiriaeva A; Zhou ZH; Chen XS
Sci Adv; 2023 Jan; 9(1):eade3168. PubMed ID: 36598981
[TBL] [Abstract][Full Text] [Related]
42. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
[TBL] [Abstract][Full Text] [Related]
43. Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC.
Zuo T; Liu D; Lv W; Wang X; Wang J; Lv M; Huang W; Wu J; Zhang H; Jin H; Zhang L; Kong W; Yu X
J Virol; 2012 May; 86(10):5497-507. PubMed ID: 22379088
[TBL] [Abstract][Full Text] [Related]
44. Conformational Dynamics of the HIV-Vif Protein Complex.
Ball KA; Chan LM; Stanley DJ; Tierney E; Thapa S; Ta HM; Burton L; Binning JM; Jacobson MP; Gross JD
Biophys J; 2019 Apr; 116(8):1432-1445. PubMed ID: 30961890
[TBL] [Abstract][Full Text] [Related]
45. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
Yu X; Yu Y; Liu B; Luo K; Kong W; Mao P; Yu XF
Science; 2003 Nov; 302(5647):1056-60. PubMed ID: 14564014
[TBL] [Abstract][Full Text] [Related]
46. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif.
Xiao Z; Ehrlich E; Yu Y; Luo K; Wang T; Tian C; Yu XF
Virology; 2006 Jun; 349(2):290-9. PubMed ID: 16530799
[TBL] [Abstract][Full Text] [Related]
47. APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated.
Dang Y; Siew LM; Zheng YH
J Biol Chem; 2008 May; 283(19):13124-31. PubMed ID: 18326044
[TBL] [Abstract][Full Text] [Related]
48. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
Pery E; Rajendran KS; Brazier AJ; Gabuzda D
J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
[TBL] [Abstract][Full Text] [Related]
49. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif.
Walker RC; Khan MA; Kao S; Goila-Gaur R; Miyagi E; Strebel K
J Virol; 2010 May; 84(10):5201-11. PubMed ID: 20219919
[TBL] [Abstract][Full Text] [Related]
50. Maedi-visna virus Vif protein uses motifs distinct from HIV-1 Vif to bind zinc and the cofactor required for A3 degradation.
Knecht KM; Hu Y; Rubene D; Cook M; Ziegler SJ; Jónsson SR; Xiong Y
J Biol Chem; 2021; 296():100045. PubMed ID: 33465707
[TBL] [Abstract][Full Text] [Related]
51. Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors.
Huang W; Zuo T; Jin H; Liu Z; Yang Z; Yu X; Zhang L; Zhang L
Mol Divers; 2013 May; 17(2):221-43. PubMed ID: 23378232
[TBL] [Abstract][Full Text] [Related]
52. APOBEC3-mediated editing in HIV type 1 from pediatric patients and its association with APOBEC3G/CUL5 polymorphisms and Vif variability.
De Maio FA; Rocco CA; Aulicino PC; Bologna R; Mangano A; Sen L
AIDS Res Hum Retroviruses; 2012 Jun; 28(6):619-27. PubMed ID: 22145963
[TBL] [Abstract][Full Text] [Related]
53. Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis.
Lavens D; Peelman F; Van der Heyden J; Uyttendaele I; Catteeuw D; Verhee A; Van Schoubroeck B; Kurth J; Hallenberger S; Clayton R; Tavernier J
Nucleic Acids Res; 2010 Apr; 38(6):1902-12. PubMed ID: 20015971
[TBL] [Abstract][Full Text] [Related]
54. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex.
Shirakawa K; Takaori-Kondo A; Kobayashi M; Tomonaga M; Izumi T; Fukunaga K; Sasada A; Abudu A; Miyauchi Y; Akari H; Iwai K; Uchiyama T
Virology; 2006 Jan; 344(2):263-6. PubMed ID: 16303161
[TBL] [Abstract][Full Text] [Related]
55. STUB1/CHIP promotes ubiquitination and degradation of HIV-1 Vif to restore the cellular level of APOBEC3G protein.
Ali A; Kumar V; Banerjea AC
Biochem Biophys Res Commun; 2021 Oct; 574():27-32. PubMed ID: 34425283
[TBL] [Abstract][Full Text] [Related]
56. Structural insights for HIV-1 therapeutic strategies targeting Vif.
Salter JD; Morales GA; Smith HC
Trends Biochem Sci; 2014 Sep; 39(9):373-80. PubMed ID: 25124760
[TBL] [Abstract][Full Text] [Related]
57. Molecular insight into the conformational dynamics of the Elongin BC complex and its interaction with HIV-1 Vif.
Marcsisin SR; Engen JR
J Mol Biol; 2010 Oct; 402(5):892-904. PubMed ID: 20728451
[TBL] [Abstract][Full Text] [Related]
58. Characterization of Cullin-box sequences that direct recruitment of Cul2-Rbx1 and Cul5-Rbx2 modules to Elongin BC-based ubiquitin ligases.
Mahrour N; Redwine WB; Florens L; Swanson SK; Martin-Brown S; Bradford WD; Staehling-Hampton K; Washburn MP; Conaway RC; Conaway JW
J Biol Chem; 2008 Mar; 283(12):8005-13. PubMed ID: 18187417
[TBL] [Abstract][Full Text] [Related]
59. Adenovirus E4orf6 assembles with Cullin5-ElonginB-ElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53.
Luo K; Ehrlich E; Xiao Z; Zhang W; Ketner G; Yu XF
FASEB J; 2007 Jun; 21(8):1742-50. PubMed ID: 17351129
[TBL] [Abstract][Full Text] [Related]
60. ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction.
Miyakawa K; Matsunaga S; Kanou K; Matsuzawa A; Morishita R; Kudoh A; Shindo K; Yokoyama M; Sato H; Kimura H; Tamura T; Yamamoto N; Ichijo H; Takaori-Kondo A; Ryo A
Nat Commun; 2015 Apr; 6():6945. PubMed ID: 25901786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]